Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Use of intensity-modulated radiation therapy for nasopharyngeal cancer in Japan: analysis using a national database.

Rikitake R, Tsukada Y, Ando M, Yoshida M, Iwamoto M, Yamasoba T, Higashi T.

Jpn J Clin Oncol. 2019 Jul 1;49(7):639-645. doi: 10.1093/jjco/hyz042.

PMID:
31505652
2.

Metachronous and Synchronous Cancers in Patients with Neuroendocrine Tumors.

Verrico M, Rossi L, Tomao S, Colonna M, Vici P, Tomao F.

Oncology. 2019 Sep 10:1-6. doi: 10.1159/000502384. [Epub ahead of print]

PMID:
31505502
3.

Tales from topographic oceans: topologically associated domains and cancer.

Campbell MJ.

Endocr Relat Cancer. 2019 Sep 1. pii: ERC-19-0348. doi: 10.1530/ERC-19-0348. [Epub ahead of print] Review.

PMID:
31505466
4.

Variation in the use of single- versus multi-fractions palliative radiotherapy for bone metastases in Australia.

Ong WL, Foroudi F, Milne RL, Millar JL.

Int J Radiat Oncol Biol Phys. 2019 Sep 7. pii: S0360-3016(19)33750-2. doi: 10.1016/j.ijrobp.2019.08.061. [Epub ahead of print]

PMID:
31505246
5.

Comparison of deep learning-based and patch-based methods for pseudo-CT generation in MRI-based prostate dose planning.

Largent A, Barateau A, Nunes JC, Mylona E, Castelli J, Lafond C, Greer PB, Dowling JA, Baxter J, Saint-Jalmes H, Acosta O, Crevoisier R.

Int J Radiat Oncol Biol Phys. 2019 Sep 7. pii: S0360-3016(19)33735-6. doi: 10.1016/j.ijrobp.2019.08.049. [Epub ahead of print]

PMID:
31505245
6.

A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer cells Promotes Tumor Progression in Bone.

Kim B, Kim H, Jung S, Moon A, Noh DY, Lee ZH, Kim HJ, Kim HH.

J Bone Miner Res. 2019 Sep 10. doi: 10.1002/jbmr.3869. [Epub ahead of print]

PMID:
31505052
7.

Neither hormonal factors nor AGEs explain lower prostate cancer risk in older men with diabetes mellitus.

Chan YX, Alfonso H, Fegan PG, Flicker L, Yeap BB.

J Clin Endocrinol Metab. 2019 Jul 23. pii: jc.2019-01142. doi: 10.1210/jc.2019-01142. [Epub ahead of print]

PMID:
31504635
8.

Prostate Specific Antigen Levels during Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.

Cunningham GR, Ellenberg SS, Bhasin S, Matsumoto AM, Parsons JK, Preston P, Cauley JA, Gill TM, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Pahor M, Crandall JP, Molitch ME, Cifelli D, Basaria S, Diem SJ, Stephens-Shields AJ, Hou X, Snyder PJ.

J Clin Endocrinol Metab. 2019 Jul 23. pii: jc.2019-00806. doi: 10.1210/jc.2019-00806. [Epub ahead of print]

PMID:
31504596
9.

Mortality among Italian male workers in the construction industry: a census-based cohort study.

Alicandro G, Bertuccio P, Sebastiani G, La Vecchia C, Frova L.

Eur J Public Health. 2019 Sep 3. pii: ckz129. doi: 10.1093/eurpub/ckz129. [Epub ahead of print]

PMID:
31504442
10.

DeepCOP - Deep Learning-Based Approach to Predict Gene Regulating Effects of Small Molecules.

Woo G, Fernandez M, Hsing M, Lack NA, Cavga AD, Cherkasov A.

Bioinformatics. 2019 Aug 26. pii: btz645. doi: 10.1093/bioinformatics/btz645. [Epub ahead of print]

PMID:
31504186
11.

Dried Fruit Intake and Cancer: A Systematic Review of Observational Studies.

Mossine VV, Mawhinney TP, Giovannucci EL.

Adv Nutr. 2019 Aug 26. pii: nmz085. doi: 10.1093/advances/nmz085. [Epub ahead of print]

PMID:
31504082
12.

Systematically understanding the immunity leading to CRPC progression.

Ji Z, Zhao W, Lin HK, Zhou X.

PLoS Comput Biol. 2019 Sep 10;15(9):e1007344. doi: 10.1371/journal.pcbi.1007344. [Epub ahead of print]

13.

Molecular determinants of response to high dose androgen therapy in prostate cancer.

Nyquist MD, Corella A, Mohamad O, Coleman I, Kaipainen A, Kuppers DA, Lucas JM, Paddison PJ, Plymate SR, Nelson PS, Mostaghel EA.

JCI Insight. 2019 Sep 10. pii: 129715. doi: 10.1172/jci.insight.129715. [Epub ahead of print]

14.

Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.

Vellky JE, Bauman TM, Ricke EA, Huang W, Ricke WA.

Prostate. 2019 Sep 10. doi: 10.1002/pros.23906. [Epub ahead of print]

PMID:
31503366
15.

Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.

Roberto D, Selvarajah S, Park PC, Berman D, Venkateswaran V.

Prostate. 2019 Sep 10. doi: 10.1002/pros.23903. [Epub ahead of print]

PMID:
31503357
16.

Comparative toxicity outcomes of proton-beam therapy versus intensity-modulated radiotherapy for prostate cancer in the postoperative setting.

Santos PMG, Barsky AR, Hwang WT, Deville C, Wang X, Both S, Bekelman JE, Christodouleas JP, Vapiwala N.

Cancer. 2019 Sep 10. doi: 10.1002/cncr.32457. [Epub ahead of print]

PMID:
31503338
17.

Proton-beam therapy after radical prostatectomy: Continued DVH idolatry?

Lee WR.

Cancer. 2019 Sep 10. doi: 10.1002/cncr.32456. [Epub ahead of print] No abstract available.

PMID:
31503326
18.

Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer.

Rosiello G, Bandini M, Briganti A.

Curr Opin Urol. 2019 Sep 9. doi: 10.1097/MOU.0000000000000674. [Epub ahead of print]

PMID:
31503189
19.

The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy.

Faisal FA, Lotan TL.

Adv Anat Pathol. 2019 Sep 9. doi: 10.1097/PAP.0000000000000245. [Epub ahead of print]

PMID:
31503032
20.

Variation in MRI-Ultrasound Fusion Targeted Biopsy Outcomes in Asian-American Men: A Multi-Center Study.

Gross MD, Marks LS, Sonn GA, Green DA, Wang GJ, Shoag JE, Cabezon E, Margolis DJ, Robinson BD, Hu JC.

J Urol. 2019 Sep 10:101097JU0000000000000534. doi: 10.1097/JU.0000000000000534. [Epub ahead of print]

PMID:
31502942

Supplemental Content

Loading ...
Support Center